Rockwell Medical, Inc. (NASDAQ:RMTI)
| Market Cap | $23.12M-36.1% |
| Revenue (ttm) | $72.58M-4.0% |
| Net Income | -$5.66M-2.5% |
| EPS | -$1.48+8.1% |
| Shares Out | 3.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51,381 |
| Open | $6.01 |
| Previous Close | $6.26 |
| Day's Range | $5.81 - $6.29 |
| 52-Week Range | $4.89 - $12.90 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | $20.00(+243.64%) |
| Earnings Date | Mar 25, 2027 |
About RMTI
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating RMTI in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 25, 2027Earnings report
$RMTI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RMTI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RMTI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RMTI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
RMTI Revenue by Segment or Geography
| Revenue recorded | $19.12M | 62.25% |
| Accounts receivable, net | $9.80M | 31.89% |
| Customer A | $1.40M | 4.56% |
| Products Purchase Agreement | $400.00K | 1.30% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New RMTI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RMTI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RMTI
| VTIVanguard Morningstar Total Stock Market ETF | $470.71K |
| VXFVanguard Extended Market ETF | $253.92K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RMTI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings beat on revenue with 20% sales growth; loss reported but top-line expectations exceeded, suggesting operational momentum.
